← Back to patent-cliff list
Paclitaxel/Hyaluronic acid
Tier C — Watch / tradePaclitaxel/Hyaluronic acid
Fidia Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：CD44, Tubulin
Indications (approved)：Bladder cancer, 乳头状癌
Regional status
US
Phase III
2022-12-29
EU
Phase III
2022-12-29
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Paclitaxel/Hyaluronic acid?
Approved indications include: Bladder cancer, 乳头状癌.
When does the Paclitaxel/Hyaluronic acid patent expire?
No public expiry year is available for Paclitaxel/Hyaluronic acid yet; this page updates once verified.
How do I get a quote for Paclitaxel/Hyaluronic acid intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21